Source: Eur Respir J, 55 (4) 1901694; 10.1183/13993003.01694-2019
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Naomi E. Wijker, Suzanna Vidmar, Keith Grimwood, Peter D. Sly, Catherine A. Byrnes, John B. Carlin, Peter J. Cooper, Colin F. Robertson, R. John Massie, Mariette P.C. Kemner van de Corput, Joyce Cheney, Harm A.W.M. Tiddens, Claire E. Wainwright. Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort. Eur Respir J, 55 (4) 1901694; 10.1183/13993003.01694-2019

Member's Comments

No comment yet.

Related content which might interest you: Risk factors for lung disease progression in children with cystic fibrosis; a longitudinal cohort study Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring Year: 2017 Early determinants of lung disease in children with cystic fibrosis Source: Virtual Congress 2020 – New frontiers in cystic fibrosis imaging and lung physiology Year: 2020 Season dynamics of inflammatory markers in patients with cystic fibrosis lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 528s Year: 2002 Persistent lung abnormalities versus established fibrosis: a prospective study of COVID-19 follow-up Source: Virtual Congress 2021 – Long COVID - 19 Year: 2021 Early cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 77-87 Year: 2014 Screening for cystic fibrosis among high risk group patients with chronic lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 340s Year: 2002 Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF): analysis from the Swedish IPF registry Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2008; 32: 170-174 Year: 2008 Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes Source: Eur Respir J, 55 (4) 2000105; 10.1183/13993003.00105-2020 Year: 2020 Monitoring early lung disease in cystic fibrosis: where are we now? Source: Breathe 2014; 10: 34-47 Year: 2014 Longitudinal assessment of Lung Clearance Index as a marker of disease progression in a cohort of children with cystic fibrosis and normal spirometry Source: Virtual Congress 2020 – New frontiers in cystic fibrosis imaging and lung physiology Year: 2020 Lung cancer in combined pulmonary fibrosis and emphysema: a large retrospective cohort analysis Source: ERJ Open Res, 6 (4) 00521-2020; 10.1183/23120541.00521-2020 Year: 2020 Assessment of fibrosis in lung biopsies from the European childhood interstitial lung disease (chILD) registry Source: Virtual Congress 2020 – Possible scenarios in the challenging future of rare diffuse parenchymal lung diseases Year: 2020 Quality of life in cystic fibrosis patients before and after lung transplantation: a longitudinal study Source: Eur Respir J 2002; 20: Suppl. 38, 343s Year: 2002 Risk factors for lung disease progression in children with cystic fibrosis Source: Eur Respir J, 51 (6) 1702509; 10.1183/13993003.02509-2017 Year: 2018 Risk factors for lung disease progression in children with cystic fibrosis Source: Eur Respir J, 52 (4) 1801492; 10.1183/13993003.01492-2018 Year: 2018 Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021 One-year follow-up for lung function and functional capacity in cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 183s Year: 2005 The diagnosis of cystic fibrosis in adult COPD patients. A survey of 54 patients Source: Eur Respir J 2001; 18: Suppl. 33, 215s Year: 2001 The clinical value of surgical lung biopsy in 166 patients with suspected interstitial lung disease Source: International Congress 2015 – New insights into IIPs Year: 2015